Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and leukemia group B trial 9430

Journal of Thoracic Oncology

Volumn 3, Issue 11, 2008, Pages 1301-1307

  Stinchcombe, Thomas E ^a   Mauer, Ann M ^b   Hodgson, Lydia D ^c   Herndon, James E ^c   Lynch, Thomas J ^d   Green, Mark R ^e   Vokes, Everett E ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CALGB; Chemotherapy; Lung cancer; Paclitaxel; Small cell lung cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; LEUKEMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MALAISE; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SURVIVAL RATE;

EID: 58949103542     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318187494a     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
3. Evans WK, Feld R, Osoba D, Shepherd FA, Dill J, Deboer G. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 1984;53:1461-1466.
4. Schiller J, Adak S, Cella D, Devore R, Johnson D. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
5. Hanna N, Sandier A, Loehrer PS, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with eto-poside plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002;13:95- 102.
6. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of cancer Lung cancer Cooperative Group. J Clin Oncol 1993;11:1230-1240.
7. Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005;97:666-674.
8. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclo-phosphamide, doxorubicin, and vincristine versus etoposide and cispla-tin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
9. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophos-phamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861.
10. Noda K, Nishiwaki A, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell-lung cancer. N Engl J Med 2002;346:85-91.
11. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044- 2051.
12. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
13. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006;24:4840- 4847.
14. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13: 1430-1435.
15. Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999;22:517-522.
16. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lungII cancer. Br J Cancer 1998;77:347-351.
17. Graziano SL, Herndon JE II, Socinski MA, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol 2008;3:158-162.
18. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:3752-3759.
19. Lyss AP, Herndon JE II, Lynch TJ Jr, et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 2002;3: 205-210, discussion 11-12.
20. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-248.
21. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharma-cologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993;11:2010-2020.
22. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
23. Mitchell EP, Perry MC, Luikart SD, et al. A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. Lung Cancer 1996;15:215-223.
24. Wasserheit C, Frazein A, Oratz R, et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996;14:1993-1999.
25. Bonomi P, Kim K, Fairclough D. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
26. Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer. J Clin Oncol 2001;19: 1320-1325.
27. Gridelli C, Manzione L, Perrone F, et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 2001;84:38-41.
28. de Jong WK, Groen HJ, Koolen MG, et al. Phase III study of cyclo-phosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. Eur J Cancer 2007;43:2345-2350.
29. Baka S, Mullamitha S, Ashcroft L, Nagel S, Board R, Lorigan P. Randomized phase III study of carboplatin and paclitaxel versus vin-cristine, doxorubicin and cyclophosphamide chemotherapy in intermediate and poor prognosis small cell lung cancer: preliminary results. J Clin Oncol (Meeting Abstracts) 2006;24(Suppl 18):7059.